Have a feature idea you'd love to see implemented?
Let us know!
KYMR Kymera Therapeutics Inc
Price (delayed)
$43.51
Market cap
$2.82B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
$2.79B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
The equity has soared by 126% YoY and by 30% from the previous quarter
KYMR's gross profit has surged by 87% year-on-year
KYMR's debt is up by 9% year-on-year
KYMR's net income is down by 6% since the previous quarter
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
64.77M
Market cap
$2.82B
Enterprise value
$2.79B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.01
Price to sales (P/S)
37.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.86
Revenue
$87.56M
EBIT
-$167.23M
EBITDA
-$160.96M
Free cash flow
-$148.2M
Per share
Balance sheet
Liquidity
EPS
-$2.34
Free cash flow per share
-$1.95
Book value per share
$14.46
Revenue per share
$1.15
TBVPS
$13.59
Total assets
$1.03B
Total liabilities
$141.91M
Debt
$88.23M
Equity
$892.93M
Working capital
$502.18M
Debt to equity
0.1
Current ratio
8.55
Quick ratio
8.35
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-183.8%
Gross margin
100%
Net margin
-191.3%
Operating margin
-228.6%
Return on assets
-20.3%
Return on equity
-25%
Return on invested capital
-22.5%
Return on capital employed
-17.3%
Return on sales
-191%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
-1.23%
1 week
-5.3%
1 month
-6.55%
1 year
129.48%
YTD
70.9%
QTD
-8.07%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$87.56M
Gross profit
$87.56M
Operating income
-$200.19M
Net income
-$167.47M
Gross margin
100%
Net margin
-191.3%
KYMR's gross profit has surged by 87% year-on-year
KYMR's revenue has soared by 87% YoY
KYMR's net margin is up by 46% year-on-year but it is down by 7% since the previous quarter
The operating margin has grown by 42% YoY but it has contracted by 9% from the previous quarter
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
3.01
P/S
37.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.86
The company's EPS rose by 18% YoY and by 3.3% QoQ
The equity has soared by 126% YoY and by 30% from the previous quarter
The stock's price to book (P/B) is 33% less than its 5-year quarterly average of 4.5 and 6% less than its last 4 quarters average of 3.2
KYMR's revenue has soared by 87% YoY
The price to sales (P/S) is 26% higher than the last 4 quarters average of 30.1 and 23% higher than the 5-year quarterly average of 30.7
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales rose by 46% YoY but it fell by 7% QoQ
The company's return on equity rose by 34% YoY and by 13% QoQ
The return on invested capital has grown by 31% year-on-year and by 10% since the previous quarter
KYMR's return on assets is up by 29% year-on-year and by 9% since the previous quarter
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total assets has soared by 87% YoY and by 25% from the previous quarter
Kymera Therapeutics's quick ratio has increased by 45% YoY
KYMR's debt is 90% smaller than its equity
The equity has soared by 126% YoY and by 30% from the previous quarter
Kymera Therapeutics's debt to equity has plunged by 50% YoY and by 23% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.